Extended infusion of dripenem for sepsis in hepatopoietic stem cell transplantatation; pharmacokinetic study

Extended infusion of dripenem for sepsis in hepatopoietic stem cell transplantatation; pharmacokinetic study - Extended infusion of dripenem; pharmacokinetic study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013478

Enrollment

Registered

2014-04-01

Start date

2013-09-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis in hematopoietic stem cell transplantatation

Interventions

Extended infusion (4 hour) of dripenem Analysis of blood concentration (dripenem)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient received hematopoietic stem cell transplantatation for hematological malignancy 2. 20-year old or older 3. Patient using central venous catheter

Exclusion criteria

Exclusion criteria: 1. Allergic history of carbapenem or beta-lactam antibiotics 2. Hepatic disorder with grade II or above 3. Renal disorder; less than 70ml/min./1.73m2 (eGFR) 4. Prophylactic antibiotics for bacterial infection except for quinolones 5. Treatment with antifungal drugs 6. Ineligible decision by physician 7. Repeated inclusion of patient 8. Patient without central venous catheter

Design outcomes

Primary

Measure	Time frame
High time above MIC in extnded infusion (4 hour) of dripenem (3g/day)	—

Countries

Japan

Contacts

Public ContactAkihito Shinohara

Graduate school of medicine, The university of Tokyo Department of hematology and oncology

sinohaa-tky@umin.ac.jp+81-3-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026